Posted by Michael Wonder on 16 Nov 2017
Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD
16 November 2017 - GlaxoSmithKline and Innoviva today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe. It is a combination of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta 2-adrenergic agonist, delivered once daily in GSK’s Ellipta dry powder inhaler.
The first European launch is expected to take place before the end of the year.
